Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $65

Benzinga Newsdesk www.benzinga.com Positive 81.5%

Neg 0% Neu 0% Pos 81.5%

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $50 to $65.